论文信息 - Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit - 字舞流文

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

I. Wistuba | J. Zha | L. Rangell | L. Amler | H. Koeppen | T. Januario | D. Shames | R. Yauch | S. Mohan | A. Pandita | V. Ramakrishnan | Jenny Huang | E. Filvaroff | Rajesh Patel | R. Desai | R. Raja | Xiaoling Xia | E. Penuel | S. Louie | A. Peterson | L. Fu | S. Phan | Premal H. Patel | M. Lazarov | Wei Yu | V. Parab | A. Do | M. Lipkind | Linda Rangell | An D. Do | Rupal H Desai | Vaishali Parab | Marina Lipkind